Preventive medicine and physical activity centre (centre EPIC), Montreal Heart Institute
Montreal, Quebec, H1T1N6, Canada
NCT Number: NCT04962061
The ACTIONcardioRisk trial is designed to investigate the effect of aerobic and progressive resistance training exercises combined with cognitive training, on neurocognitive functioning of sedentary older adults with and without cardiovascular risk factors.
Looking for future studies?
Notify Me60 year and older
All sexes
Interventional
Not applicable
Montreal, Quebec, H1T1N6, Canada
The proportion of older adults is on the rise in Canada, with the fastest growth recorded among those seventy years of age or older. The prevalence of cardiovascular risk factors (CVRF) such as diabetes, hypertension, and high cholesterol increases drastically with age. Individuals with CVRF often show impaired cognition, such as attention and memory deficits. In healthy older adults, exercise training and cognitive stimulation can help enhance cognitive performances. More precisely, combined intervention, including physical and cognitive training, has shown beneficial effects on cognition in older adults without cognitive impairment and with mild cognitive impairment. However, the effect of such programs on cognition in individuals with CVRF is not well documented. This project compares the effect of a physical exercise program, including aerobic and resistance training, alone or combined with cognitive training on cognitive performances and brain imaging outcomes in individuals with CVRF and healthy controls.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be encouraged to perform sessions of cognitive training 3 times per week (30 minutes/session). Two of these sessions will involve computer- or tablet-based attentional control training targeting dual-tasking, updating and working memory, as well as inhibition and switching. Difficulty of cognitive training will be tailored to participants' performances. The remaining session will consist of memory training. Participants will be instructed mnemotechnic, as well as be taught about memory in aging in general.
Participants will follow a periodized exercise training program with thrice-weekly 60 minutes trainings. The sessions will start with a 5-10mins warm-up, followed by aerobic and resistance trainings, and ends with a 5-10mins cool-down and stretching period. Intensity of aerobic sessions will be monitored with heart rate chest strap and should match with the moderate to vigorous intensity zone as defined by the ACSM (65% of Heart Rate maximum or more and a Perceived Exertion higher than 12 on the 6 to 20 Borg scale). Exercise intensity and duration will be gradually increased during the program. After aerobic training, a 15-20mins resistance training will be performed with a gradual progression of higher intensities and/or numbers of sets. The one maximal repetition (1RM) will be assessed for each RT movements at baseline, during (each 3 months) and at the end of the program. RT intensities will go from 40 to 70% of 1RM, with 8 to 10 forms of exercise involving majors muscle groups.
Participants in the active control condition will take part in three 60 minutes stretching and toning sessions per week. Each session will start with a five-minutes warm-up, followed by fifteen min of body stretching exercises mainly in a seated position and finish with a five-minutes cool down. Participants will engage in four muscle-toning exercises (light intensity) using dumbbells or resistance bands, two exercises designed to improve balance, one yoga sequence, and one exercise of their choice. Intensity of stretching and toning sessions will be monitored with heart rate chest strap and should not exceed the light intensity zone as defined by the ACSM (64% of Heart Rate maximum or less and a Perceived Exertion lower than 11 on the 6 to 20 Borg scale).
Time frame: Baseline and post-intervention at 12 months.
Montreal Cognitive Assessment (0-30 score, with a higher score indicating a better cognitive functioning).
Time frame: Baseline and post-intervention at 12 months.
Validated remote version of neuropsychological tests and iPad tests (Composite Z-score).
Time frame: Baseline and post-intervention at 12 months.
Validated remote version of neuropsychological tests and iPad tests (Composite Z-score).
Time frame: Baseline and post-intervention at 12 months.
Validated remote version of neuropsychological tests and iPad tests (Composite Z-score).
Time frame: Baseline and post-intervention at 12 months.
Variations of prefrontal cortical oxygen saturation (rSO2, [HbO]/([HbO]+[HbR])) will be measured by Near Infrared Spectroscopy (NIRS), as a surrogate of cortical blood flow. Variations of continuous peripheral blood pressure (mm Hg) will be simultaneously measured by plethysmography at the finger. Autoregulation indices (unitless) will be derived from the correlation between variations of oxygen saturation measures and variations of peripheral blood pressure.
Time frame: Baseline and post-intervention at 12 months.
Variations of cerebral blood flow velocity (cm/s) at the level of the middle cerebral artery will be measured by Transcranial Doppler (TCD). Variations of continuous peripheral blood pressure (mm Hg) will be simultaneously measured by plethysmography at the finger. Autoregulation indices (unitless) will be derived from the correlation between variations of cerebral blood flow measures and variations of peripheral blood pressure.
Time frame: Baseline and post-intervention at 12 months.
Cerebral VasoReactivity (CVR, % change per mm Hg of PaCO2) will be measured by Arterial Spin Labeling MRI in two third of the study participants who do not present contra-indication for imaging studies.
Time frame: Baseline and post-intervention at 12 months.
Cerebral VasoReactivity (CVR, % change per mm Hg of PaCO2) will be measured using NIRS in the prefrontal region.
Time frame: Baseline and post-intervention at 12 months.
Cerebral VasoReactivity (CVR, % change per mm Hg of PaCO2) will be measured using TCD in the middle cerebral arteries
Time frame: Baseline and post-intervention at 12 months.
Pulsatility will be measured as the normalized difference of relative near-infrared light intensity changes between systole and diastole, using NIRS in the prefrontal cortical region.
Time frame: Baseline and post-intervention at 12 months.
Pulsatility will be measured as the normalized difference of relative blood flow velocities between systole and diastole, using TCD in the middle cerebral arteries.
Time frame: Baseline and post-intervention at 12 months.
Significant changes in brain activity evoked by a Stroop task relative to baseline will be assessed by t-statistics maps, computed from variations of [HbO] and [HbR] measured by NIRS at the prefrontal cortex.
Time frame: Baseline and post-intervention at 12 months.
Multimodal structural MRI will be performed in two third of the study participants who do not present contra-indication for imaging studies, to measure regional cerebral volumes, as well as volume of angiopathic markers (eg lacunes, microbleeds, white matter hyperintensities), in cm3.
Time frame: Baseline and post-intervention at 12 months.
Maximum incremental cardiopulmonary exercise test (VO2 max (ml.kg.min)).
Time frame: Baseline and post-intervention at 12 months.
Fow-mediated dilation of the brachial artery (%).
Time frame: Baseline and post-intervention at 12 months.
Carotid femoral pulse-wave velocity (m/s).
Time frame: Baseline and post-intervention at 12 months.
Timed 10-meter walking test (cm/s).
Time frame: Baseline and post-intervention at 12 months.
Timed Time up and Go test (s).
Time frame: Baseline and post-intervention at 12 months.
Timed one-leg standing test (s).
Time frame: Baseline and post-intervention at 12 months.
Timed Sit-to-Stand test (s)
Time frame: Baseline and post-intervention at 12 months.
Grip strength test score (kg).
Time frame: Baseline and post-intervention at 12 months.
Total cholesterol levels (mmol/L)
Time frame: Baseline and post-intervention at 12 months.
Cholesterol-HDL levels (mmol/L)
Time frame: Baseline and post-intervention at 12 months.
Cholesterol-LDL calculated levels (mmol/L)
Time frame: Baseline and post-intervention at 12 months.
Cholesterol non-HDL levels (mmol/L)
Time frame: Baseline and post-intervention at 12 months.
Triglycerides levels (mmol/L)
Time frame: Baseline and post-intervention at 12 months.
Glucose levels (mmol/L)
Time frame: Baseline and post-intervention at 12 months.
Glycated hemoglobin (HbA1c) (%)
Time frame: Baseline and post-intervention at 12 months.
Insulin levels (pmol/L)
Time frame: Baseline and post-intervention at 12 months.
Creatinine levels (mg/dL)
Time frame: Baseline and post-intervention at 12 months.
Sodium levels (mmol/L)
Time frame: Baseline and post-intervention at 12 months.
Chloride levels (mmol/L)
Time frame: Baseline and post-intervention at 12 months.
Potassium levels (mmol/L)
Time frame: Baseline and post-intervention at 12 months.
High-sensitive C-reactive protein (hsCRP) levels (mg/L)
Time frame: Baseline and post-intervention at 12 months.
Apolipoprotein B (ApoB) levels (g/L)
Time frame: Baseline and post-intervention at 12 months.
Brain-derived neurotrophic factor (BDNF) plasma concentration (pg/mL).
Time frame: Baseline and post-intervention at 12 months.
Transcriptome analysis to assess the impact of the intervention on any changes in the activity of different cellular processes.
Time frame: Baseline and post-intervention at 12 months
DNA extraction from fecal samples. The fecal samples will be collected from the participants who are also performing MRI.
Time frame: Baseline and post-intervention at 12 months.
Cortisol levels from saliva samples (nmol/L). The saliva samples will be collected from the participants who are also performing MRI.
Time frame: Baseline and post-intervention at 12 months.
Perceived Stress Scale questionnaire (Score ranges from 0-4, with 0 no stress,1 mild stress, 3 moderate stress and 4 severe).
Time frame: Baseline and post-intervention at 12 months.
State-Trait Anxiety Inventory questionnaire (Score ranges from 20-80, with a higher score indicating higher anxiety).
Time frame: Baseline and post-intervention at 12 months.
Geriatric Depression Scale questionnaire (Score ranges from 0-30, with a higher score indicating larger depressive symptomatology).
Time frame: Baseline and post-intervention at 12 months.
12-Item Short Form Health Survey (a completer).
Time frame: Baseline and post-intervention at 12 months.
Pittsburg Sleep Quality Index questionnaire (Score ranges from 0-21, with a higher score indicating worse sleep quality).
Time frame: Baseline and post-intervention at 12 months.
Short Diet Questionnaire (Score ranges from 15-45 points, with a score between 15-29 categorised as unhealthy, 30-37 as somewhat unhealthy, and 38 or more as a healthy diet).
Time frame: Baseline and post-intervention at 12 months.
Social and community involvement questionnaire (Score ranges from 0-200, with a higher score indicating more social and community involvement).
Time frame: Baseline
Physical Activity Scale for the Elderly questionnaire (Score ranges from 0-400, with a higher score indicating better level of physical activity).
Time frame: Baseline
Short Form Bem Sex-Role Inventory questionnaire (30 items questionnaire with 10 items assessing the femininity traits, 10 items assessing the masculinity traits, and 10 items neutral, not scored. Two scores are calculated for femininity and masculinity, respectively, and range from 10-70, whit a higher score indicating a higher femininity or masculinity trait).
Time frame: Baseline
Genotyping array to generate high quality genome-wide genotyping data that include the APOE and BDNF genes.
Time frame: Baseline
Rami and colleagues' cognitive reserve questionnaire (Scale ranges from 0-26, with a higher score indicating a greater cognitive reserve).
Time frame: Baseline
Quantification of physical activity using an accelerometry recording of 7 days (minutes of moderate to vigorous activity).
Louis Bherer
Other
Impacts of Aerobic, Resistance and Cognitive Training Interventions on Neurocognitive Functions in Older Adults With Cardiovascular Risk Factors.
Acronym: ACTIONcR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03840330
Aging, Behavior
View Trial DetailsNCT05934760
Aging, Atrophy
Derby, Derbyshire, United Kingdom
View Trial DetailsNCT07598123
Aging, Behavior
Taichung, Taiwan
View Trial DetailsNCT07714148
Aging, Behavior
Çanakkale, Turkey (Türkiye)
View Trial Details